Targeted therapies: Cetuximab, chemotherapy and KRAS status in mCRC

infusion of 5-fluorouracil and leucovorin with either oxaliplatin (FolFoX4) or irinotecan (FolFiri) is commonly recom mended by oncologists as initial combination chemotherapy for previously untreated patients with metastatic colo rectal cancer (mCrC). with the advent of targeted therapies, however, bevacizumab, a humanized mono clonal antibody that binds… CONTINUE READING